DRAMP_ID	Sequence	Sequence_Length	Name	Swiss_Prot_Entry	Family	Gene	Source	Activity	Protein_existence	Structure	Structure_Description	PDB_ID	Comments	Target_Organism	Hemolytic_activity	Linear/Cyclic/Branched	N-terminal_Modification	C-terminal_Modification	Other_Modifications	Stereochemistry	Cytotoxicity	Binding_Traget	Pubmed_ID	Reference	Author	Title
DRAMP03591	ACYCRIPACIAGERRYGTCIYQGRLWAFCC	30	"Neutrophil defensin 1 (Defensin, alpha 1; HNP-1, HP-1; Human, mammals, animals)"	"P59665, P11479, Q14125, Q6EZF6"	Belongs to the alpha-defensin family	"DEFA1, DEFA1B"	Homo sapiens (Human)	"Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram-, Antifungal, Antiviral(SARS-CoV-2)"	Protein level	Beta strand	"Compared to HNP-2, HNP-1 contains one additional residue (Ala) at the N-terminus. It contains a long stretch of a double-stranded antiparallel beta-sheet in a hairpin conformation that contains a beta-bulge, a short region of triple-stranded beta-sheet, and several tight turns."	2KHT resolved by NMR	"Function: Defensin 1 and defensin 2 have antibacterial, fungicide and antiviral activities. Has antimicrobial activity against Gram-negative and Gram-positive bacteria. Defensins are thought to kill microbes by permeabilizing their plasma membrane.
PTM: ADP-ribosylation drastically reduces cytotoxic and antibacterial activities, and enhances IL8 production. Phosphorylation at Tyr-85 has been found in some cancer cell lines, and interferes with ADP-rybosylation."	"[Ref.34206990]Virus:SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 ¦Ìg/mL (290 nM));SARS-CoV-2 variant P.1:inhibition of infection in HeLa-hACE2 cells(67% inbibition at 50 ¦Ìg/mL);SARS-CoV-2 variant B.1.1.7:inhibition of infection in HeLa-hACE2 cells(58% inbibition at 50 ¦Ìg/mL).##[Ref.15616305] Gram-negative bacteria: Escherichia coli ATCC 8739 (vLD50=3.6¡À0.3 ¦Ìg/ml), E. coli ATCC 25922 (vLD50=3.7¡À0.4 ¦Ìg/ml), Enterobacter aerogenes ATCC 13048 (vLD50=10¡À0.5 ¦Ìg/ml);##Gram-positive bacteria: Staphylococcus aureus ATCC 25923 (vLD50=4.2¡À1.0 ¦Ìg/ml), Staphylococcus aureus ATCC 29213 (vLD50=2.1¡À0.3 ¦Ìg/ml), Bacillus cereus ATCC 10876 (vLD50=0.22¡À0.03 ¦Ìg/ml).##NOTE: vLD50, virtual lethal doses (vLDs), equivalent to conventional 50% lethal doses (LD50s).##[Ref.15118082]Gram-positive bacteria: Bacillus subtilis (Inhibition zone=24 mm in PH5.5, Inhibition zone=20 mm in PH7.5 completely inhibit at 10 ¦Ìg/well), Staphylococcus aureus  (Inhibition zone=1 mm in PH5.5, Inhibition zone=7 mm incompletely inhibit and Inhibition zone=2 mm completely inhibit in PH7.5 at 10 ¦Ìg/well);##Gram-negative bacteria: Escherichia coli (Inhibition zone=5 mm incompletely inhibit and Inhibition zone=2 mm completely inhibit in PH7.5 at 10 ¦Ìg/well);##Fungi: Candida albicans (Inhibition zone=13 mm in PH5.5, Inhibition zone=10 mm in PH7.5 completely inhibit at 10 ¦Ìg/well)."	No hemolysis information or data found in the reference(s) presented in this entry	Cyclic	Free	Cyclization(Cys2 and Cys30).	"Disulfide bonds between Cys2 and Cys30,Cys4 and Cys19,Cys9 and Cys29."	L	[Ref.34206990]No cytotoxicity on HEK293T cells up to 50 ¦Ìg/mL.	Not found	34206990##19253295##15616305##15118082	Viruses. 2021 Jun 26;13(7):1246.##Proteomics. 2009 Mar;9(5):1364-1373.##Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.##Proc Natl Acad Sci U S A. 2004 May 11;101(19):7363-8.	"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.##Stegemann C, Kolobov A Jr, Leonova YF, Knappe D, Shamova O, Ovchinnikova TV, Kokryakov VN, Hoffmann R.##Ericksen B, Wu Z, Lu W, Lehrer RI.##Yount NY, Yeaman MR."	"Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.##Isolation, purification and de novo sequencing of TBD-1, the first beta-defensin from leukocytes of reptiles.##Antibacterial activity and specificity of the six human {alpha}-defensins.##Multidimensional signatures in antimicrobial peptides."
DRAMP03592	CYCRIPACIAGERRYGTCIYQGRLWAFCC	29	"Neutrophil defensin 2 (HNP-2, HP-2, HP2; Human, mammals, animals)"	"P59665, P11479, Q14125, Q6EZF6, P59666, P11479, Q14125"	Belongs to the alpha-defensin family	DEFA1 AND DEFA1B	Homo sapiens (Human)	"Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram-, Antifungal, Antiviral(SARS-CoV-2)"	Protein level	Beta strand	Not found	"1ZMH, 1ZMI, 1ZMK resolved by X-ray."	"Function: Defensin 2 have antibiotic, fungicide and antiviral activities. Has antimicrobial activity against Gram-negative and Gram-positive bacteria. Defensins are thought to kill microbes by permeabilizing their plasma membrane.
PTM: Contains three disulfide bonds 1-29; 3-18; 8-28."	"[Ref.34206990]Virus:SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 ¦Ìg/mL (290 nM)).##Gram-negative bacteria: Escherichia coli ATCC 8739 (vLD50=3.5¡À0.79 ?g/ml), E. coli ATCC 25922 (vLD50=3.5¡À0.6 ?g/ml), Enterobacter aerogenes ATCC 13048 (vLD50=16¡À4.0 ?g/ml);##Gram-positive bacteria: Staphylococcus aureus ATCC 25923 (vLD50=4.2¡À0.9 ?g/ml), S. aureus ATCC 29213 (vLD50=2.4¡À0.3 ?g/ml), Bacillus cereus ATCC 10876 (vLD50=0.22¡À0.04 ?g/ml).(Ref.2)##NOTE: vLD50, virtual lethal doses (vLDs), equivalent to conventional 50% lethal doses (LD50s)."	No hemolysis information or data found in the reference(s) presented in this entry	Cyclic	No specific N-terminal	No specific C-terminal	"Disulfide bonds between Cys1 and Cys29,Cys3 and Cys18,Cys8 and Cys28."	L	No cytotoxicity information found in the reference(s) presented	Not found	34206990##15616305##15894545	Viruses. 2021 Jun 26;13(7):1246.##Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.##J Biol Chem. 2005 Sep 23;280(38):32921-9.	"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.##Ericksen B, Wu Z, Lu W, Lehrer RI.##Xie C, Prahl A, Ericksen B, Wu Z, Zeng P, Li X, Lu WY, Lubkowski J, Lu W."	Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.##Antibacterial activity and specificity of the six human {alpha}-defensins.##Reconstruction of the conserved beta-bulge in mammalian defensins using D-amino acids.
DRAMP03593	DCYCRIPACIAGERRYGTCIYQGRLWAFCC	30	"Neutrophil defensin 3 (Defensin, alpha 3; HNP-3, HP-3, HP3; Human, mammals, animals)"	"P59666, P11479, Q14125"	Belongs to the alpha-defensin family	DEFA3	Homo sapiens (Human)	"Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram-, Antifungal, Antiviral(SARS-CoV-2)"	Protein level	Beta strand	"Compared to HNP-2, HNP-3 contains one additional residue (Asp) at the N-terminus. The 3D structures remain the same. "	"1DFN, 2PM4, 2PM5 resolved by X-ray."	"Function: Defensin 3 have antibiotic, fungicide and antiviral activities. Has antimicrobial activity against Gram-negative and Gram-positive bacteria. Defensins are thought to kill microbes by permeabilizing their plasma membrane.
PTM: Contains three disulfide bonds 2-30; 4-19; 9-29."	"[Ref.34206990]Virus:SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 ¦Ìg/mL (290 nM)).##Gram-negative bacteria: Escherichia coli ATCC 8739 (vLD50=6.2¡À0.9 ?g/ml), E. coli ATCC 25922 (vLD50=5.9¡À2.1 ?g/ml), Enterobacter aerogenes ATCC 13048 (vLD50=41¡À9.2 ?g/ml);##Gram-positive bacteria: Staphylococcus aureus ATCC 25923 (vLD50=13¡À2.1 ?g/ml), S. aureus ATCC 29213 (vLD50=2.2¡À0.4 ?g/ml), Bacillus cereus ATCC 10876 (vLD50=0.37¡À0.08 ?g/ml).(Ref.2)##NOTE: vLD50, virtual lethal doses (vLDs), equivalent to conventional 50% lethal doses (LD50s)."	No hemolysis information or data found in the reference(s) presented in this entry	Cyclic	Free	Cyclization(Cys2 and Cys30).	"Disulfide bonds between Cys2 and Cys30,Cys4 and Cys19,Cys9 and Cys29."	L	No cytotoxicity information found in the reference(s) presented	Not found	34206990##4056036##15616305	Viruses. 2021 Jun 26;13(7):1246.##J Clin Invest. 1985 Oct;76(4):1436-1439.##Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.	"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.##Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI.##Ericksen B, Wu Z, Lu W, Lehrer RI."	Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.##Primary structures of three human neutrophil defensins.##Antibacterial activity and specificity of the six human {alpha}-defensins.
DRAMP03594	VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV	33	"Neutrophil defensin 4 (Defensin, alpha 4; HNP-4, HP-4; Human, mammals, animals)"	P12838	Belongs to the alpha-defensin family	DEFA4	Homo sapiens (Human)	"Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram-, Antifungal, Antiviral(SARS-CoV-2)"	Protein level	Beta strand	"Compared to HNP-2, HNP-1 contains one additional residue (Ala) at the N-terminus. It contains a long stretch of a double-stranded antiparallel beta-sheet in a hairpin conformation that contains a beta-bulge, a short region of triple-stranded beta-sheet, and several tight turns."	1ZMM resolved by X-ray.	"Function: Has antimicrobial activity against Gram-negative bacteria, and to a lesser extent also against Gram-positive bacteria and fungi. Protects blood cells against infection with HIV-1 (in vitro). In comparison with HNP1-3, inhibition of both strains of HIV-1 by HNP4 was noticeably stronger as evidenced by lower IC50 values (2-5 ?M) and steeper and more complete inhibition curves.
PTM: Contains three disulfide bonds 2-30; 4-19; 9-29."	"[Ref.34206990]Virus:showed inhibition against SARS-CoV-2.Gram-negative bacteria: Escherichia coli ATCC 8739 (vLD50=3.3¡À0.4 ?g/ml), E. coli ATCC 25922 (vLD50=3.0¡À0.7 ?g/ml), Enterobacter aerogenes ATCC 13048 (vLD50=6.6¡À0.2 ?g/ml);##Gram-positive bacteria: Staphylococcus aureus ATCC 25923 (vLD50=7.3¡À1.4 ?g/ml), S. aureus ATCC 29213 (vLD50=7.2¡À0.2 ?g/ml), Bacillus cereus ATCC 10876 (vLD50=0.87¡À0.08 ?g/ml).(Ref.4)##NOTE: vLD50, virtual lethal doses (vLDs), equivalent to conventional 50% lethal doses (LD50s).##Yeast: Candida albicans ATCC 99788 amphotericin B resistant (IC90>100 ?g/ml).(Ref.2)"	No hemolysis information or data found in the reference(s) presented in this entry	Cyclic	Free	Free	"Disulfide bonds between Cys2 and Cys30,Cys4 and Cys19,Cys9 and Cys29."	L	No cytotoxicity information found in the reference(s) presented	Not found	34206990##17088326##15620707##15616305	Viruses. 2021 Jun 26;13(7):1246.##Protein Sci. 2006 Dec;15(12):2749-2760.##FEBS Lett. 2005 Jan 3;579(1):162-166.##Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.	"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.##Szyk A, Wu Z, Tucker K, Yang D, Lu W, Lubkowski J.##Wu Z, Cocchi F, Gentles D, Ericksen B, Lubkowski J, Devico A, Lehrer RI, Lu W.##Ericksen B, Wu Z, Lu W, Lehrer RI."	"Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.##Crystal structures of human alpha-defensins HNP4, HD5, and HD6.##Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in vitro.##Antibacterial activity and specificity of the six human {alpha}-defensins."
DRAMP03595	ATCYCRTGRCATRESLSGVCEISGRLYRLCCR	32	"Human defensin-5 (HD-5; Defensin, alpha 5; Human, mammals, animals)"	"Q01523, A0JDY6, Q3KNV2"	Belongs to the alpha-defensin family	DEFA5	Homo sapiens (Human)	"Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram-, Antifungal, Antiviral(SARS-CoV-2)"	Protein level	Beta strand	The L- and D-forms of HD-5 are equally active than E.coli but not S. aureus (Wei G et al 2009 JBC 284: 29180-92). 	1ZMP resolved by X-ray.	"Function: Antimicrobial activity against Gram-negative and Gram-positive bacteria. Defensins are thought to kill microbes by permeabilizing their plasma membrane. All DEFA5 peptides exert antimicrobial activities, but their potency is affected by peptide processing.
Tissue specificity: Paneth cells of the small intestine (at protein level).
PTM: Contains three disulfide bonds."	"[Ref.34206990]Virus:SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(60% inhibition at 12.5 ¦Ìg/mL (3.45 ¦ÌM));SARS-CoV-2 variant P.1:inhibition of infection in HeLa-hACE2 cells(72% inbibition at 50 ¦Ìg/mL);SARS-CoV-2 variant B.1.1.7:inhibition of infection in HeLa-hACE2 cells(32% inbibition at 50 ¦Ìg/mL).##Gram-negative bacteria: Escherichia coli ATCC 8739 (vLD50=2.5¡À0.3 ?g/ml), E. coli ATCC 25922 (vLD50=2.1¡À0.9 ?g/ml), Enterobacter aerogenes ATCC 13048 (vLD50=5.5¡À0.5 ?g/ml);##Gram-positive bacteria: Staphylococcus aureus ATCC 25923 (vLD50=6.3¡À0.5 ?g/ml), S. aureus ATCC 29213 (vLD50=3.2¡À0.3 ?g/ml), Bacillus cereus ATCC 10876 (vLD50<0.31 ?g/ml).(Ref.2)##NOTE: vLD50, virtual lethal doses (vLDs), equivalent to conventional 50% lethal doses (LD50s)."	[Ref.26206286] It has 0% hemolysis at 100¦ÌM against human red blood cells.	Cyclic	Free	Free	"Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30."	L	[Ref.34206990]No cytotoxicity on HEK293T cells up to 50 ¦Ìg/mL.	Not found	34206990##12021776##15616305##26206286	Viruses. 2021 Jun 26;13(7):1246.##Nat Immunol. 2002 Jun;3(6):583-590.##Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.##Peptides. 2015 Sep;71:128-40. doi: 10.1016/j.peptides.2015.07.009. Epub 2015 Jul 20.	"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.##Ghosh D, Porter E, Shen B, Lee SK, Wilk D, Drazba J, Yadav SP, Crabb JW, Ganz T, Bevins CL.##Ericksen B, Wu Z, Lu W, Lehrer RI.##Basil Mathew Ramakrishnan Nagaraj"	Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.##Paneth cell trypsin is the processing enzyme for human defensin-5.##Antibacterial activity and specificity of the six human {alpha}-defensins.##Antimicrobial activity of human  -defensin 5 and its linear analogs: N-terminal fatty acylation results in enhanced antimicrobial activity of the linear analogs
DRAMP03596	AFTCHCRRSCYSTEYSYGTCTVMGINHRFCCL	32	"Human defensin-6 (HD-6; Defensin, alpha 6; Human, mammals, animals)"	Q01524	Belongs to the alpha-defensin family	DEFA6	Homo sapiens (Human)	"Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram-, Antifungal, Antiviral(SARS-CoV-2)"	Protein level	Beta strand (3 strands; 19 residues)	Not found	"1ZMQ, 3QTE resolved by X-ray."	"Function: Has very low antimicrobial activity against Gram-negative and Gram-positive bacteria. May protect cells against infection with HIV-1.
Subunit structure: Homodimer.
Tissue specificity: Paneth cells of the small intestine.
PTM: Contains three disulfide bonds."	"[Ref.34206990]Virus:SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(HD6 only blocked SARS-CoV-2 infection at the highest concentration tested (50 ¦Ìg/mL, 13 ¦ÌM)).##Gram-negative bacteria: Escherichia coli ATCC 8739 (vLD50>256 ?g/ml), E. coli ATCC 25922 (vLD50=103¡À14 ?g/ml), Enterobacter aerogenes ATCC 13048 (vLD50=156¡À11 ?g/ml);##Gram-positive bacteria: Staphylococcus aureus ATCC 25923 (vLD50>256 ?g/ml), S. aureus ATCC 29213 (vLD50>256 ?g/ml), Bacillus cereus ATCC 10876 (vLD50=25¡À13 ?g/ml).(Ref.3)##NOTE: vLD50, virtual lethal doses (vLDs), equivalent to conventional 50% lethal doses (LD50s)."	No hemolysis information or data found in the reference(s) presented in this entry	Cyclic	Free	Free	"Disulfide bonds between Cys4 and Cys31,Cys6 and Cys20,Cys10 and Cys30."	L	[Ref.34206990]No cytotoxicity on HEK293T cells up to 50 ¦Ìg/mL.	Not found	34206990##8417977##17088326##15616305	Viruses. 2021 Jun 26;13(7):1246.##FEBS Lett. 1993; 315:187-192.##Protein Sci. 2006 Dec;15(12):2749-2760.##Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.	"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.##Jones DE, Bevins CL.##Szyk A, Wu Z, Tucker K, Yang D, Lu W, Lubkowski J.##Ericksen B, Wu Z, Lu W, Lehrer RI."	"Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.##Defensin-6 mRNA in human Paneth cells: implications for antimicrobial peptides in host defense of the human bowel.##Crystal structures of human alpha-defensins HNP4, HD5, and HD6.##Antibacterial activity and specificity of the six human {alpha}-defensins."
DRAMP29151	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL	36	EK1	Q8BB25	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Hemology	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.35087243]Virus:##SARS-CoV-2 Omicron:inhibition of cell-cell fusion in Calu-3 cells(IC50=119.68 nM);inhibition of cell-cell infusion in Caco2 cells(IC50=74.99 nM);inhibition of infection(Pseudovirus)(IC50=309.4 nM);inhibition of infection(Authentic)(IC50=1138 nM);##SARS-CoV-2 Delta:inhibition of cell-cell fusion(IC50=131.8?nM);inhibition of infection(Pseudovirus)(IC50=427.55?nM);##SARS-CoV-2 D614G:inhibition of cell-cell fusion(IC50=314.6?nM);inhibition of infection(Pseudovirus)(IC50=414.85?nM).##[Ref.32231345]Virus:##SARS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=409.3 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=3237 nM);##MERS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=239.5 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=631.8 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=802.1 nM);##HCoV-OC43:ihibition of cell-cell fusion in Huh-7 cells(IC50=787.6 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=1398 nM),inhibit the replication of HCoV-OC43 in RD cells(IC50=1554 nM);##HCoV-229E:ihibition of cell-cell fusion in Huh-7 cells(IC50=207.4 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=3963 nM),inhibit the replication of HCoV-229E in Huh-7 cells(IC50=4375 nM);##HCoV-NL63:ihibition of cell-cell fusion in Huh-7 cells(IC50=751.0 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=7666 nM),inhibit the replication of HCoV-NL63 in LLC-MK2 cells(IC50=3693 nM);##CoV-WIV1:ihibition of cell-cell fusion in Huh-7 cells(IC50=265.7 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=5425 nM);##CoV-Rs3367:ihibition of cell-cell fusion in Huh-7 cells(IC50=237.0 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=6014 nM);##CoV-SHC014:ihibition of cell-cell fusion in Huh-7 cells(IC50=279.6 nM);##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=286.7-315.0 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=2375.0 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=2468 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	35087243##32231345##30989115##32047258	Cell Res. 2022 Apr;32(4):404-406.##Cell Res. 2020 Apr;30(4):343-355.##Sci Adv. 2019 Apr 10;5(4):eaav4580.##Cell Mol Immunol. 2020 Jul;17(7):765-767.	"Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.##Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.##Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L.##Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L."	Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.##Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.##A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.##Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein.
DRAMP29152	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL	36	EK1P	Q8BB25	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Hemology	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	[Ref.32231345]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=69.2 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG4-C(Palm)	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32231345	Cell Res. 2020 Apr;30(4):343-355.	"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L."	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
DRAMP29153	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL	36	EK1C	Q8BB25	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Hemology	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.32231345]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=37.3-48.1 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=139.4 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG4-C(Chol)	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32231345	Cell Res. 2020 Apr;30(4):343-355.	"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L."	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
DRAMP29154	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL	36	EK1C1	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.32231345]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=56.8 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=480.3 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32231345	Cell Res. 2020 Apr;30(4):343-355.	"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L."	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
DRAMP29155	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG	39	EK1C2	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.32231345]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=48.2 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=418.6 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32231345	Cell Res. 2020 Apr;30(4):343-355.	"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L."	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
DRAMP29156	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG	39	EK1C3	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.32231345]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=10.6 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=86.4 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG4-Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32231345	Cell Res. 2020 Apr;30(4):343-355.	"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L."	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
DRAMP29157	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG	41	EK1C4	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.35087243]Virus:##SARS-CoV-2 Omicron:inhibition of cell-cell fusion in Calu-3 cells(IC50=3.32 nM);inhibition of cell-cell infusion in Caco2 cells(IC50=0.88 nM);inhibition of infection(Pseudovirus)(IC50=8.63 nM);inhibition of infection(Authentic)(IC50=85.38 nM);##SARS-CoV-2 Delta:inhibition of cell-cell fusion(IC50=4.04?nM);inhibition of infection(Pseudovirus)(IC50=9.83?nM);##SARS-CoV-2 D614G:inhibition of cell-cell fusion(IC50=2.57?nM);inhibition of infection(Pseudovirus)(IC50=5.58?nM).##[Ref.32231345]Virus:##SARS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=4.3 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=11.7 nM);##MERS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=2.5 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=11.1 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=4.2 nM);##HCoV-OC43:ihibition of cell-cell fusion in Huh-7 cells(IC50=7.7 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=37.7 nM),inhibit the replication of HCoV-OC43 in RD cells(IC50=24.8 nM);##HCoV-229E:ihibition of cell-cell fusion in Huh-7 cells(IC50=5.2 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=12.4 nM),inhibit the replication of HCoV-229E in Huh-7 cells(IC50=101.5 nM);##HCoV-NL63:ihibition of cell-cell fusion in Huh-7 cells(IC50=21.4 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=76.6 nM),inhibit the replication of HCoV-NL63 in LLC-MK2 cells(IC50=187.6 nM);##CoV-WIV1:ihibition of cell-cell fusion in Huh-7 cells(IC50=4.5 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=30.8 nM);##CoV-Rs3367:ihibition of cell-cell fusion in Huh-7 cells(IC50=8.1 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=66.9 nM);##CoV-SHC014:ihibition of cell-cell fusion in Huh-7 cells(IC50=4.3 nM);##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=1.3 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=15.8 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=2468 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG4-Chol	None	L	"[Ref.32231345]<10% cytotoxicity against VERO-E6 cells, RD cells, LLC-MK2 cells, Huh-7 cells up to 10000 nM."	liposomes	35087243##32231345	Cell Res. 2022 Apr;32(4):404-406.##Cell Res. 2020 Apr;30(4):343-355.	"Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.##Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L."	Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.##Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
DRAMP29158	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG	41	EK1C5	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.32231345]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.1 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=31.3 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32231345	Cell Res. 2020 Apr;30(4):343-355.	"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L."	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
DRAMP29159	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG	41	EK1C6	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.32231345]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.9 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=77.4 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG12-Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32231345	Cell Res. 2020 Apr;30(4):343-355.	"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L."	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
DRAMP29160	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG	41	EK1C7	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.32231345]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.9 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=84.4 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG24-Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32231345	Cell Res. 2020 Apr;30(4):343-355.	"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L."	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
DRAMP29161	LKVLLYEEFKLLESLIMEILEYQKDSDIKENAEDTK	36	EK1-scrambled	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.32231345]Virus:SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-OC43,HCoV-229E,HCoV-NL63,CoV-WIV1,CoV-Rs3367,CoV-SHC014(No inhibition on the concentration up to 10 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32231345	Cell Res. 2020 Apr;30(4):343-355.	"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L."	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
DRAMP29162	NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGC	40	EKL1C	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"EKL1C is a Peptide-based pan-CoV fusion inhibitor,targets a highly conserved target site in HR1 domains in S protein of HCoVs."	"[Ref.35087243]Virus:##SARS-CoV-2 Omicron:inhibition of cell-cell fusion in Calu-3 cells(IC50=12.18 nM);inhibition of cell-cell infusion in Caco2 cells(IC50=5.52 nM);inhibition of infection(Pseudovirus)(IC50=26.14 nM);inhibition of infection(Authentic)(IC50=182.2 nM);##SARS-CoV-2 Delta:inhibition of cell-cell fusion(IC50=14.42?nM);inhibition of infection(Pseudovirus)(IC50=31.99?nM);##SARS-CoV-2 D614G:inhibition of cell-cell fusion(IC50=11.77?nM);inhibition of infection(Pseudovirus)(IC50=23.6?nM).##[Ref.34367893]Virus:##SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.045¡À0.006 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.037¡À0.009 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.040¡À0.005 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=0.008¡À0.001 ¦Ìmol/L);inhibited authentic SARS-CoV-2 infection in Vero E6 cells(IC50=0.003¡À0.001 ¦Ìmol/L);##SARS-CoV-2 variants(inhibition of Pseudovirus(PsV) infection):V341L(IC50=0.047¡À0.013 ¦Ìmol/L);F342L(IC50=0.026¡À0.007 ¦Ìmol/L);V367F(IC50=0.066¡À0.012 ¦Ìmol/L);R408I(IC50=0.148¡À0.012 ¦Ìmol/L);N435D(IC50=0.135¡À0.013 ¦Ìmol/L);G476S(IC50=0.065¡À0.008 ¦Ìmol/L);V483A(IC50=0.078¡À0.011 ¦Ìmol/L);N501Y(IC50=0.069¡À0.006 ¦Ìmol/L);D614G(IC50=0.104¡À0.010 ¦Ìmol/L);12 mutations(P.1)(IC50=0.046¡À0.006 ¦Ìmol/L);K417N-E484K-N501Y(IC50=0.113¡À0.013 ¦Ìmol/L);8 mutations(B.1.1.7)(IC50=0.120¡À0.009 ¦Ìmol/L);wide type(IC50=0.049¡À0.007 ¦Ìmol/L);##inhibition of multiple HCoV Pseudovirus:SARS-CoV (IC50=0.076¡À0.014 ¦Ìmol/L), MERS-CoV(IC50=0.048¡À0.006 ¦Ìmol/L), HCoV-OC43(IC50=0.668¡À0.081 ¦Ìmol/L), HCoV-NL63(IC50=0.035¡À0.003 ¦Ìmol/L), SARSr-CoV-WIV1(IC50=0.218¡À0.013 ¦Ìmol/L), and HCoV-Rs3367 (IC50=0.046¡À0.003 ¦Ìmol/L),inhibition of authentic HCoV-OC43 infection in RD cells (IC50=0.281¡À0.018 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	[Ref.34367893]Huh-7 cells:CC50=10 ¦Ìmol/L;Caco-2 cells:CC50=13.81 ¦Ìmol/L;293T/ACE2 cells:CC50=8.49 ¦Ìmol/L.	liposomes	35087243##34367893	Cell Res. 2022 Apr;32(4):404-406.##Acta Pharm Sin B. 2021 Aug 2.	"Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.##Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.##A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29163	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG	41	EK1-C16	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	EK1-C16 at 0.31 ¦ÌM could effectively inhibit authentic SARS-CoV-2 WT infection.	[Ref.35336956]Virus:##SARS-CoV-2 WT:inhibition of pseudovirus (PsV) infection in Caco2 cells(IC50=0.48 ¦ÌM);##SARS-CoV-2 Alpha:inhibition of pseudovirus (PsV) infection(IC50=0.19 ¦ÌM);##SARS-CoV-2 Beta:inhibition of pseudovirus (PsV) infection(IC50=0.43 ¦ÌM);##SARS-CoV-2 Gamma:inhibition of pseudovirus (PsV) infection(IC50=0.26 ¦ÌM);##SARS-CoV-2 Delta:inhibition of pseudovirus (PsV) infection(IC50=0.11 ¦ÌM);##SARS-CoV-2 Omicron:inhibition of pseudovirus (PsV) infection(IC50=0.23 ¦ÌM);inhibition of authentic infection in Vero-E6-TMPRSS-2 cells(IC50=0.75 ¦ÌM);##SARS-CoV:inhibition of pseudovirus (PsV) infection(IC50=0.17 ¦ÌM);##SARSr-CoV WIV1:inhibition of pseudovirus (PsV) infection(IC50=0.15 ¦ÌM);##SARSr-CoV Rs3367:inhibition of pseudovirus (PsV) infection(IC50=0.3 ¦ÌM);##MERS-CoV:inhibition of pseudovirus (PsV) infection in Caco2 cells(IC50=0.10 ¦ÌM);inhibition of cell-cell fusion(IC50=0.012 ¦ÌM);##HCoV-OC43:inhibition of authentic infection in RD cells(IC50=0.07 ¦ÌM);inhibition of cell-cell fusion(IC50=0.01 ¦ÌM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG4-C16(palmitic acid)	None	L	[Ref.35336956]showed  no significant cytotoxicity against RD cells at the concentration of 5 ¦ÌM.	Not found	35336956	Viruses. 2022 Mar 6;14(3):549.	"Lan Q, Chan JF, Xu W, Wang L, Jiao F, Zhang G, Pu J, Zhou J, Xia S, Lu L, Yuen KY, Jiang S, Wang Q. "	"A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern."
DRAMP29164	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKW	45	EKL0	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.583¡À0.073 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.442¡À0.037 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=0.277¡À0.029 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29165	NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEY	36	EKL1	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:##SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.622¡À0.089 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.746¡À0.152 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=0.220¡À0.034 ¦Ìmol/L);inhibited authentic SARS-CoV-2 infection in Vero E6 cells(IC50=1.407¡À0.189 ¦Ìmol/L);##inhibition of multiple HCoV Pseudovirus:SARS-CoV (IC50=6.716¡À5.937 ¦Ìmol/L), MERS-CoV(IC50=4.086¡À0.345 ¦Ìmol/L), HCoV-OC43(IC50=10.530¡À3.778 ¦Ìmol/L), HCoV-NL63(IC50=3.700¡À0.222 ¦Ìmol/L), SARSr-CoV-WIV1(IC50=30.270¡À4.713 ¦Ìmol/L), and HCoV-Rs3367 (IC50=88.300¡À24.600 ¦Ìmol/L),inhibition of authentic HCoV-OC43 infection in RD cells (IC50=20.290¡À1.092 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29166	TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYV	36	EKL2	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.526¡À0.049 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=4.714¡À1.173 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=1.240¡À0.246 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29167	LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKW	36	EKL3	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50>10 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50>5 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=2.167¡À0.270 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29168	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGC	49	EKL0C	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.122¡À0.012 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.147¡À0.055 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.162¡À0.022 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=0.021¡À0.003 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29169	TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVGSGC	40	EKL2C	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.115¡À0.019 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.054¡À0.014 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.200¡À0.020 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=0.022¡À0.001 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29170	LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGC	40	EKL3C	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.127¡À0.293 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=1.176¡À1.230 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.892¡À0.069 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=0.045¡À0.004 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29171	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGK	49	EKL0P	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.093¡À0.012 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.619¡À0.341 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.176¡À0.019 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=0.083¡À0.009 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Palm	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29172	NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGK	40	EKL1P	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.182¡À0.034 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.812¡À0.182 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.231¡À0.022 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=0.064¡À0.004 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Palm	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29173	TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVGSGK	40	EKL2P	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=1.129¡À0.166 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.973¡À0.254 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.304¡À0.051 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=0.183¡À0.028 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Palm	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29174	LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGK	40	EKL3P	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The peptide targets a highly conserved target site in HR1 domains in S protein of HCoVs.	"[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=3.987¡À0.682 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 ¦Ìmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=2.214¡À0.371 ¦Ìmol/L),inhibition of cell-cell fusion(IC50=0.193¡À0.021 ¦Ìmol/L)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Palm	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34367893	Acta Pharm Sin B. 2021 Aug 2.	"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q."	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
DRAMP29175	DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL	36	"2019-nCoV-HR2P(SARS-CoV-2-S(1168-1203),SARS-HR2P)"	Q5DIC5	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Hemology	Alpha helix	Not found	None	Mechanism of action:2019-nCoV HR1 and HR2 regions are able to interact with each other to form 6-HB and suggest that 2019-nCoV-HR2P may inhibit 2019-nCoV fusion with and entry into the target cell.	"[Ref.32047258]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in Huh-7 cells(IC50=0.18 ?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.98 ?M).##[Ref.30989115]SARS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=0.52¡À0.11	?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=2.81	?M);##MERS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 ?M);##HCoV-OC43:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 ?M);##HCoV-229E:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 ?M);##HCoV-NL63:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 ?M);##CoV-WIV1:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=2.73 ?M);##CoV-Rs3367:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.05 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	30989115##32047258	Sci Adv. 2019 Apr 10;5(4):eaav4580.##Cell Mol Immunol. 2020 Jul;17(7):765-767.	"Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L.##Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L."	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.##Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein.
DRAMP29176	NGAICWGPCPTAFRQIGNCGHFKVRCCKIR	30	MBD-4 (11-40)(P9)	P82019	Belongs to the beta-defensin family.	Defb4	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	6M56	Mechanism of action:Mechanistic studies show that positively charged P9 broadly inhibits viral replication by binding to different viruses and then inhibits virus¨Chost endosomal acidification to prevent the endosomal release of pH-dependent viruses. 	[Ref.32843628]Virus:##SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=2.4 ?g/ml);##SARS-CoV:Inhibition of infection in Vero E6 cells(IC50=6.2 ?g/ml);##MERS-CoV:Inhibition of infection in Vero E6 cells(IC50=8.8 ?g/ml);##Human rhinovirus (HRV):inhibition of infection in RD cells(IC50=34 ?g/ml);##Human parain?uenza virus 3:Inhibition of infection in LLC-MK2 cells(IC50>25 ?g/ml);##Human Influenza A Virus H1N1:Inhibition of infection In MDCK cells(IC50=1.6 ?g/ml);##Human Influenza A Virus H7N9:Inhibition of infection In MDCK cells(IC50=3.3 ?g/ml).##[Ref.26911565]Virus:Human Influenza A Virus H1N1(IC50=1.2 ?g/ml);Human Influenza A Virus H3N2(IC50=1.2 ?g/ml);Human Influenza A Virus H5N1(IC50=2.4 ?g/ml);Human Influenza A Virus H7N7(IC50=0.8 ?g/ml);Human Influenza A Virus H7N9(IC50=4.6 ?g/ml);MERS-CoV(IC50=4.8 ?g/ml);SARS-CoV(IC50=4.8 ?g/ml)	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	[Ref.26911565]Xytotoxicity against Madin-Darby canine kidney cells(TC50=380 ¦Ìg/ml).	Not found	26911565##32843628	Sci Rep. 2016 Feb 25;6:22008. ##Nat Commun. 2020 Aug 25;11(1):4252.	"Zhao H, Zhou J, Zhang K, Chu H, Liu D, Poon VK, Chan CC, Leung HC, Fai N, Lin YP, Zhang AJ, Jin DY, Yuen KY, Zheng BJ.##Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY."	A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. ##A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2.
DRAMP29177	NGAICWGPCPTAFRQIGNCGRFRVRCCRIR	30	"MBD-4 (11-40) (P9 [H21R,K23R,K28R], P9R)"	P82019	Belongs to the beta-defensin family.	Defb5	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	6M56	Mechanism of action:Mechanistic studies show that positively charged P9R broadly inhibits viral replication by binding to different viruses and then inhibits virus¨Chost endosomal acidification to prevent the endosomal release of pH-dependent viruses. 	[Ref.32843628]Virus:##SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=0.9 ?g/ml);##SARS-CoV:Inhibition of infection in Vero E6 cells(IC50=4.2 ?g/ml);##MERS-CoV:Inhibition of infection in Vero E6 cells(IC50=22 ?g/ml);##Human rhinovirus (HRV):inhibition of infection in RD cells(IC50=5.7 ?g/ml);##Human parain?uenza virus 3:Inhibition of infection in LLC-MK2 cells(IC50>25 ?g/ml);##Human Influenza A Virus H1N1:Inhibition of infection In MDCK cells(IC50=0.6 ?g/ml);##Human Influenza A Virus H7N9:Inhibition of infection In MDCK cells(IC50=0.9 ?g/ml).	[Ref.32843628]P9R did not cause the hemolysis of Chicken red blood cells.	Linear	Free	Free	None	L	"[Ref.32843628]the CC50 of P9R was >300?¦Ìg/ml for MDCK, VeroE6 and A549 cells."	Not found	32843628	Nat Commun. 2020 Aug 25;11(1):4252.	"Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY."	A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2.
DRAMP29178	NGAICWGPCPTAFRQIGNCGRFRVRCCRIR	30	8P9R(branched P9R)	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:Have dual-antiviral mechanisms of cross-linking viruses to stop viral entry (mediated by TMPRSS2 for SARS-CoV-2) and of reducing endosomal acidification to inhibit viral entry through endocytic pathway.	[Ref.33750821]Virus:SARS-CoV-2:inhibition of replication in high salt condition(IC50?=?0.3?¦Ìg/ml)	[Ref.33750821]no obvious hemolysis was observed when turkey red blood cells were treated at 200?¦Ìg/ml.	Branched	Free	Free	None	L	[Ref.33750821]Vero-E6 cells:the cytotoxicity indicated that TC50 of 8P9R was higher than 200?¦Ìg/ml.	Not found	33750821	Nat Commun. 2021 Mar 9;12(1):1517. 	"Zhao H, To KKW, Lam H, Zhou X, Chan JF, Peng Z, Lee ACY, Cai J, Chan WM, Ip JD, Chan CC, Yeung ML, Zhang AJ, Chu AWH, Jiang S, Yuen KY."	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2.
DRAMP29179	ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL	35	"IPB01(SARS-CoV-S (1151-1185),SR9, SARS-CoV-2-S (1169-1203))"	"P59594,P0DTC2"	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Alpha helix	Not found	None	"Mechanism of action:The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently."	"[Ref.32376627]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.022¡À0.005 ?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=33.74¡À11.827 ?M);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 ?M);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 ?M).##[Ref.17942557]Virus:SARS-CoV:Inhibition of virus entry in VERO-E6 cells(EC50=0.005 ?M).##[Ref.18442051]Virus:SARS-CoV: inhibition of PsV entry in Vero-E6 cells(EC50=0.34 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	17942557##18442051##32376627	J Virol. 2008 Jan;82(1):588-92.##J Cell Biochem. 2008 Aug 15;104(6):2335-47.##J Virol. 2020 Jul 1;94(14):e00635-20.	"Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F. ##Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM. ##Zhu Y, Yu D, Yan H, Chong H, He Y."	"Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway.##Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.##Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity."
DRAMP29180	ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK	36	IPB02(SARS-CoV-2-S (1169-1203)-K)	"P59594,P0DTC2"	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Alpha helix	Not found	None	"Mechanism of action:The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently."	"[Ref.32376627]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.025 ¡À 0.002 ?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.08¡À0.017 ?M);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=0.251 ¡À 0.118 ?M);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32376627	J Virol. 2020 Jul 1;94(14):e00635-20.	"Zhu Y, Yu D, Yan H, Chong H, He Y."	"Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity."
DRAMP29181	INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK	34	IPB03(SARS-CoV-2-S (1172-1205))	"P59594,P0DTC2"	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Alpha helix	Not found	None	"Mechanism of action:The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently."	"[Ref.32376627]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.015 ¡À 0.002 ?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.947 ¡À 0.179 ?M);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.315 ¡À 0.463 ?M);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32376627	J Virol. 2020 Jul 1;94(14):e00635-20.	"Zhu Y, Yu D, Yan H, Chong H, He Y."	"Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity."
DRAMP29182	SVVNIQKEIDRLNEVAKNLNESLIDLQELGK	31	IPB04(SARS-CoV-2-S (1175-1205))	"P59594,P0DTC2"	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Alpha helix	Not found	None	"Mechanism of action:The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently."	"[Ref.32376627]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.033 ¡À 0.013 ?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.218 ¡À 0.063 ?M);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.053 ¡À 0.444 ?M);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32376627	J Virol. 2020 Jul 1;94(14):e00635-20.	"Zhu Y, Yu D, Yan H, Chong H, He Y."	"Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity."
DRAMP29183	IQKEIDRLNEVAKNLNESLIDLQELGK	27	IPB05(SARS-CoV-2-S (1179-1205))	"P59594,P0DTC2"	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	"Mechanism of action:The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently."	"[Ref.32376627]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50>5 ?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>25 ?M);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC>25 ?M);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32376627	J Virol. 2020 Jul 1;94(14):e00635-20.	"Zhu Y, Yu D, Yan H, Chong H, He Y."	"Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity."
DRAMP29184	IDRLNEVAKNLNESLIDLQELGK	23	IPB06(SARS-CoV-2-S (1183-1205))	"P59594,P0DTC2"	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	"Mechanism of action:The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently."	"[Ref.32376627]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50>5 ?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>25 ?M);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC>25 ?M);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32376627	J Virol. 2020 Jul 1;94(14):e00635-20.	"Zhu Y, Yu D, Yan H, Chong H, He Y."	"Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity."
DRAMP29185	IQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK	33	IPB07(SARS-CoV-2-S (1179-1211))	"P59594,P0DTC2"	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Alpha helix	Not found	None	"Mechanism of action:The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently."	"[Ref.32376627]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.017 ¡À 0.001 ?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.993 ¡À 0.08 ?M);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.037 ¡À 0.836 ?M);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32376627	J Virol. 2020 Jul 1;94(14):e00635-20.	"Zhu Y, Yu D, Yan H, Chong H, He Y."	"Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity."
DRAMP29186	ISGINASVVNIQKEIDRLNEVAKNLNESLIK	31	IPB08(SARS-CoV-2-S (1169-1198)-K)	"P59594,P0DTC2"	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	"Mechanism of action:The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently."	"[Ref.32376627]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=4.66 ¡À 1.565 ?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=1.738 ¡À 0.898 ?M);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.13 ¡À 0.472 ?M);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32376627	J Virol. 2020 Jul 1;94(14):e00635-20.	"Zhu Y, Yu D, Yan H, Chong H, He Y."	"Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity."
DRAMP29187	SVVNIQKEIDRLNEVAKNLNESLIK	25	IPB09(SARS-CoV-2-S (1175-1198)-K)	"P59594,P0DTC2"	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	"Mechanism of action:The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently."	"[Ref.32376627]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50>5 ?M),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>25 ?M);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC>25 ?M);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	32376627	J Virol. 2020 Jul 1;94(14):e00635-20.	"Zhu Y, Yu D, Yan H, Chong H, He Y."	"Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity."
DRAMP29188	DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFELAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVR	85	AHB1	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. 	[Ref.32907861]Virus:SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=35 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	32907861	Science. 2020 Oct 23;370(6515):426-431.	"Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. "	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.
DRAMP29189	ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKSDDEREIREIEEEARRILEHLEELARK	75	AHB2	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. 	[Ref.32907861]Virus:SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=15.5 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	32907861	Science. 2020 Oct 23;370(6515):426-431.	"Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. "	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.
DRAMP29190	DKEWILQKIYEIMRLLDELGHAEASMRVSDLIYEFMKKGDERLLEEAERLLEEVER	56	LCB1	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. 	[Ref.32907861]Virus:SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=23.54 pM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	32907861	Science. 2020 Oct 23;370(6515):426-431.	"Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. "	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.
DRAMP29191	NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLEKVVEELKELLERLLS	64	LCB3	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. 	[Ref.32907861]Virus:SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=48.1 pM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	32907861	Science. 2020 Oct 23;370(6515):426-431.	"Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. "	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.
DRAMP29192	TFLDKFNHEAEDLFYQ	16	ACE2 (27-42)(SAP1)	Q9BYF1	Belongs to the peptidase M2 family.	ACE2	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	Mechanism of action:Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.	[Ref.33356169]Virus:##SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50=2.39¡À0.20 mM);Inhibition of infection in 293T/ACE2/GFP cells(IC50=3 mM);##SARS-CoV:Inhibition of infection in 293T/ACE2 cells(80% inhibition at 3 mM);##Vesicular Stomatitis Virus (VSV):No nhibition of infection in 293T/ACE2 cells up to 3 mM;##HCoV-NL63:Inhibition of cytopathic effect in LLC-MK2 cells(30% Inhibition at 3 mM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	33356169	Bioconjug Chem. 2021 Jan 20;32(1):215-223.	"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A."	Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
DRAMP29193	EDLFYQSSL	9	ACE2 (37-45)(SAP2)	Q9BYF1	Belongs to the peptidase M3 family.	ACE2	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	Mechanism of action:Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.	[Ref.33356169]Virus:##SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50=3.72¡À0.37 mM)	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	33356169	Bioconjug Chem. 2021 Jan 20;32(1):215-223.	"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A."	Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
DRAMP29194	LAQMYPL	7	ACE2 (79-85)(SAP3)	Q9BYF1	Belongs to the peptidase M4 family.	ACE2	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	Mechanism of action:Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.	[Ref.33356169]Virus:##SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50>7.5 mM)	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	33356169	Bioconjug Chem. 2021 Jan 20;32(1):215-223.	"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A."	Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
DRAMP29195	GKGDFRIL	8	ACE2 (352-359)(SAP4)	Q9BYF1	Belongs to the peptidase M5 family.	ACE2	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	Mechanism of action:Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.	[Ref.33356169]Virus:##SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50>7.5 mM)	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	33356169	Bioconjug Chem. 2021 Jan 20;32(1):215-223.	"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A."	Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
DRAMP29196	QAKTFLDKFNHEA	13	ACE2 (24-36)(SAP5)	Q9BYF1	Belongs to the peptidase M6 family.	ACE2	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	Mechanism of action:Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.	[Ref.33356169]Virus:##SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50>7.5 mM);No nhibition of infection in 293T/ACE2/GFP cells up to 3 mM;##SARS-CoV:Inhibition of infection in 293T/ACE2 cells(30% inhibition at 3 mM);##Vesicular Stomatitis Virus (VSV):No nhibition of infection in 293T/ACE2 cells up to 3 mM.	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	33356169	Bioconjug Chem. 2021 Jan 20;32(1):215-223.	"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A."	Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
DRAMP29197	EDLFYQ	6	ACE2 (37-42)(SAP6)	Q9BYF1	Belongs to the peptidase M4 family.	ACE2	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	Mechanism of action:Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.	[Ref.33356169]Virus:##SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50=1.9¡À0.14 mM);Inhibition of infection in 293T/ACE2/GFP cells(IC50=3 mM);##SARS-CoV:Inhibition of infection in 293T/ACE2 cells(85% inhibition at 3 mM);##Vesicular Stomatitis Virus (VSV):No nhibition of infection in 293T/ACE2 cells up to 3 mM;##HCoV-NL63:Inhibition of cytopathic effect in LLC-MK2 cells(30% Inhibition at 3 mM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	33356169	Bioconjug Chem. 2021 Jan 20;32(1):215-223.	"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A."	Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
DRAMP29198	DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGC	42	SARS-CoV-2-S(1168¨C1203)-GSGSGC	P0DTC2	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	Mechanism of action:The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. 	"[Ref.33082259]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50=10¡À8 nM,IC90=98¡À57 nM),inhibition of infection in Vero E6 cells(IC50~ 6 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=8¡À4 nM,IC90=96¡À50 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50=6¡À4 nM,IC90=75¡À42 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50=9¡À7 nM,IC90=78¡À59 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50=35¡À10 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 3 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=7¡À5 nM,IC90=43¡À6 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	"[Ref.33082259]Human embryonic kidney HEK293T cells:18% Cytotoxicity at 10 ?M;Vero E6 cells:12% Cytotoxicity at 1 ?M,30% Cytotoxicity at 10 ?M;Human airway epithelial cells:25% Cytotoxicity at 1 ?M."	liposomes	33082259##33597220	mBio. 2020 Oct 20;11(5):e01935-20.##Science. 2021 Mar 26;371(6536):1379-1382.	"Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M.##de Vries RD, Schmitz KS, Bovier FT, Predella C, Khao J, Noack D, Haagmans BL, Herfst S, Stearns KN, Drew-Bear J, Biswas S, Rockx B, McGill G, Dorrello NV, Gellman SH, Alabi CA, de Swart RL, Moscona A, Porotto M."	Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.##Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets.
DRAMP29199	SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGSGSGC	42	MERS-CoV-HR2P-GSGSGC	"R9UQ53,K9N5Q8"	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	Mechanism of action:The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. 	"[Ref.33082259]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50>650 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 36 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=1000 nM,IC90>1000 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50>1000,IC90>1000 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50>700 nM,IC90>1000 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50=417¡À180 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 4 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=40¡À34 nM,IC90>700 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	[Ref.33082259]Human embryonic kidney HEK293T cells:<10% Cytotoxicity at 10 ?M;Vero E6 cells:12% Cytotoxicity at 10 ?M.	liposomes	33082259	mBio. 2020 Oct 20;11(5):e01935-20.	"Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M."	Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.
DRAMP29200	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSGC	42	EK1-GSGSGC	Q8BB25	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Hemology	Not found	Not found	None	Mechanism of action:The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. 	"[Ref.33082259]Virus:##SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50=293¡À60 nM,IC90>900 nM),inhibition of infection in Vero E6 cells(IC50~ 41 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=261¡À136 nM,IC90=892¡À100 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50=286¡À104 nM,IC90>1000 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50=194¡À107 nM,IC90=893¡À77 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50>1000 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 2 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=36¡À5 nM,IC90>1000 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	[Ref.33082259]Human embryonic kidney HEK293T cells:<5% Cytotoxicity at 10 ?M;Vero E6 cells:18% Cytotoxicity at 10 ?M.	liposomes	33082259	mBio. 2020 Oct 20;11(5):e01935-20.	"Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M."	Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.
DRAMP29201	ANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQ	42	SARS-CoV-2 HR1P	P0DTC2	Belongs to the betacoronaviruses spike protein family.	S	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Protein level	Not found	Not found	None	Mechanism of action:The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.	"[Ref.32047258]Virus:SARS-CoV-2(No inhibition of cell-cell fusion up to 40 ?M in Huh-7 cells,No inhibition of infection up to 40 ?M in 293T/ACE2 cells)"	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	32047258	Cell Mol Immunol. 2020 Jul;17(7):765-767.	"Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L."	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein.
DRAMP29202	PHSCN	5	ATN-161	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide inhibits the spike protein interaction with ¦Á5¦Â1 integrin and the interaction between ¦Á5¦Â1 integrin and ACE2.	[Ref.33102950]Virus:SARS-CoV-2:inhibition of replication In VeroE6 cells(IC50=3.16 ?M).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Acylation	Amidation	None	L	No cytotoxicity information found in the reference(s) presented	Not found	33102950	JACC Basic Transl Sci. 2021 Jan;6(1):1-8.	"Beddingfield BJ, Iwanaga N, Chapagain PP, Zheng W, Roy CJ, Hu TY, Kolls JK, Bix GJ."	"The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection."
DRAMP29203	RVKR	4	CMK	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"Mechanism of action:CMK blocks virus entry, but it further suppresses cleavage of spikes and the syncytium."	"[Ref.33007239]Virus:SARS-CoV-2:inhibition of virus production in Vero E6 cells(IC50=0.057	 ?M).##[Ref.31683742]Virus:Zika virus (ZIKV):inhibition of virus release in Vero cells(IC50=18.59 ?M);Japanese encephalitis virus (JEV):inhibition of virus release in BHK-21 cells(IC50=19.91 ?M).##[Ref.23617302]Virus:Hepatitis B virus (HBV):Inhibition of HBeAg secretion in HepG2.2.15 cells(26¡À11% inhibition at 20 ?M,21¡À13% Inhibition at 100 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Decanoyl(C10)	chloromethylketone(CMK)	None	L	[Ref.31683742]Vero cells:CC50=712.9 ?M.[Ref.33007239]Vero E6 cells:IC50=318.2 ?M.	Not found	23617302##31683742##33007239	Liver Int. 2013 Sep;33(8):1230-8. ##Viruses. 2019 Oct 31;11(11):1011.##Cell Rep. 2020 Oct 13;33(2):108254.	"Pang YJ, Tan XJ, Li DM, Zheng ZH, Lei RX, Peng XM.##Imran M, Saleemi MK, Chen Z, Wang X, Zhou D, Li Y, Zhao Z, Zheng B, Li Q, Cao S, Ye J.##Cheng YW, Chao TL, Li CL, Chiu MF, Kao HC, Wang SH, Pang YH, Lin CH, Tsai YM, Lee WH, Tao MH, Ho TC, Wu PY, Jang LT, Chen PJ, Chang SY, Yeh SH."	Therapeutic potential of furin inhibitors for the chronic infection of hepatitis B virus.##Decanoyl-Arg-Val-Lys-Arg-Chloromethylketone: An Antiviral Compound That Acts against Flaviviruses through the Inhibition of Furin-Mediated prM Cleavage.##Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. 
DRAMP29204	LQTALYALMEEIHIAALEKTWTALRHQYT	29	Covid3	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide acts as an inhibitor of the RBD¨CACE2 interaction 	[Ref.34624194]Virus:##SARS-CoV-2:inhibition of infection in Vero cells(IC50=6.56 ¡À 2.14 ¦ÌM);##SARS-CoV-2 variants B.1.1.7:inhibition of infection in Vero cells(IC50=33.40 ¡À 10.75 ¦ÌM);##SARS-CoV-2 variants B.1.351:inhibition of infection in Vero cells(IC50=11.13 ¡À 3.82 ¦ÌM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Acylation	Amidation	None	D	No cytotoxicity information found in the reference(s) presented	Not found	34624194	J Med Chem. 2021 Oct 28;64(20):14955-14967.	"Valiente PA, Wen H, Nim S, Lee J, Kim HJ, Kim J, Perez-Riba A, Paudel YP, Hwang I, Kim KD, Kim S, Kim PM. "	Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2.
DRAMP29205	RFDGKGLGIYQYMEEIEHAASRFAYFFYQHLA	32	Covid_extented_1	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The peptide acts as an inhibitor of the RBD¨CACE2 interaction	[Ref.34624194]Virus:##SARS-CoV-2:inhibition of infection in Vero cells(IC50=5.76 ¡À 1.65 ¦ÌM);##SARS-CoV-2 variants B.1.1.7:inhibition of infection in Vero cells(IC50=5.57 ¡À 4.04 ¦ÌM);##SARS-CoV-2 variants B.1.351:inhibition of infection in Vero cells(IC50=7.37 ¡À 1.80 ¦ÌM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Acylation	Amidation	None	D	No cytotoxicity information found in the reference(s) presented	Not found	34624194	J Med Chem. 2021 Oct 28;64(20):14955-14967.	"Valiente PA, Wen H, Nim S, Lee J, Kim HJ, Kim J, Perez-Riba A, Paudel YP, Hwang I, Kim KD, Kim S, Kim PM. "	Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2.
DRAMP29206	SALEEQYKTFLDKFLHELEDLLYQLALAL	29	P7	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"Mechanism of action:The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein."	[Ref.33580154]Virus:SARS-CoV-2:54% inhibition of replication in Vero-E6 cells at 10?¦ÌM;inhibition of replication in Calu-3 cells(IC50>1 ¦ÌM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Amidation	None	L	No cytotoxicity information found in the reference(s) presented	Not found	33580154	Commun Biol. 2021 Feb 12;4(1):197.	"Karoyan P, Vieillard V, G¨®mez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O."	Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.
DRAMP29207	SALEEQLKTFLDKFMHELEDLLYQLAL	27	P8	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Alpha helix	Not found	None	"Mechanism of action:The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein."	[Ref.33580154]Virus:SARS-CoV-2:91% inhibition of replication in Vero-E6 cells at 10?¦ÌM;inhibition of replication in Calu-3 cells(IC50=46 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Amidation	None	L	[Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells.	Not found	33580154	Commun Biol. 2021 Feb 12;4(1):197.	"Karoyan P, Vieillard V, G¨®mez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O."	Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.
DRAMP29208	SALEEQYKTFLDKFMHELEDLLYQLSL	27	P9	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"Mechanism of action:The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein."	[Ref.33580154]Virus:SARS-CoV-2:93% inhibition of replication in Vero-E6 cells at 10?¦ÌM;inhibition of replication in Calu-3 cells(IC50=53 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Amidation	None	L	[Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells.	Not found	33580154	Commun Biol. 2021 Feb 12;4(1):197.	"Karoyan P, Vieillard V, G¨®mez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O."	Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.
DRAMP29209	SALEEQYKTFLDKFMHELEDLLYQLAL	27	P10	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"Mechanism of action:The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein."	[Ref.33580154]Virus:SARS-CoV-2:95% inhibition of replication in Vero-E6 cells at 10?¦ÌM;inhibition of replication in Calu-3 cells(IC50=42 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Amidation	None	L	[Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells.	Not found	33580154	Commun Biol. 2021 Feb 12;4(1):197.	"Karoyan P, Vieillard V, G¨®mez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O."	Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.
DRAMP29210	RGAHIKGRWKSRCHRF	16	FBP	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	The fusion-inhibition peptide FBP could broadly inhibit influenza virus and SARS-CoV-2 by interfering the viral fusion by the endocytic pathway and showed potently antiviral activity against the influenza virus in mice and SARS-CoV-2 variants in hamsters.	"[Ref.35259078]Virus:A(H1N1)(IC50?=?3.9 ¦Ìg/ml);A(H3N2)(IC50?=?1.6 ¦Ìg/ml);FluB (IC50?=?7.1 ¦Ìg/ml);SARS-CoV-2 (HKU001a):inhibition of infection in Vero-E6 cells(IC50=2.9 ¦Ìg/ml);SARS-CoV-2 (B.1.1.63, D614G):inhibition of infection in Vero-E6 cells(IC50=3.0 ¦Ìg/ml);SARS-CoV-2(Delta):inhibition of infection in Vera-E6 cells(IC50=3.9 ¦Ìg/ml)."	[Ref.35259078]No significant hemolysis against Turkey red blood cells (RBC).	Linear	Free	Free	None	L	[Ref.35259078]No significant cytotoxicity was detected in MDCK(Madin Darby canine kidney) cells at 1 mg/ml(TC50?>?1?mg/ml).	liposomes	35259078	Emerg Microbes Infect. 2022 Dec;11(1):926-937.	"Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY."	"Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants."
DRAMP29211	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG	41	EK1P4HC	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"The peptide targets two different sites when mediating virus¨Ccell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level."	[Ref.34769299]Virus:##SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.8 ¦ÌM);##SARS-CoV-2 B.1.1.7 (Alpha):inhibition of Pseudoviruse infection in Caco2 cells(IC50=2.28 ¦ÌM);##SARS-CoV-2 B.1.351 (Beta):inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.62 ¦ÌM);##SARS-CoV-2 P.1 (Gamma):inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.48 ¦ÌM);##SARS-CoV-2 B.1.617.2 (Delta):inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.11 ¦ÌM);##HCoV-229E(Authentic):inhibition of infection in Caco2 cells(IC50=0.48 ¦ÌM);##HCoV-OC43(Authentic):inhibition of infection in Caco2 cells(IC50=0.41 ¦ÌM);##SARS-CoV:inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.35 ¦ÌM);##MERS-CoV:inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.10 ¦ÌM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG4-25-HC	None	L	[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 ¦ÌM.	liposomes	34769299	Int J Mol Sci. 2021 Nov 1;22(21):11869. 	"Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. "	"25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses."
DRAMP29212	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG	41	EK1P8HC	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"The peptide targets two different sites when mediating virus¨Ccell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level."	[Ref.34769299]Virus:SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=3.7 ¦ÌM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-25-HC	None	L	[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 ¦ÌM.	liposomes	34769299	Int J Mol Sci. 2021 Nov 1;22(21):11869. 	"Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. "	"25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses."
DRAMP29213	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG	41	EK1P12HC	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"The peptide targets two different sites when mediating virus¨Ccell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level."	[Ref.34769299]Virus:SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=5.2 ¦ÌM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG12-25-HC	None	L	[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 ¦ÌM.	liposomes	34769299	Int J Mol Sci. 2021 Nov 1;22(21):11869. 	"Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. "	"25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses."
DRAMP29214	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG	41	EK1P24HC	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"The peptide targets two different sites when mediating virus¨Ccell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level."	[Ref.34769299]Virus:SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=10.3 ¦ÌM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG24-25-HC	None	L	[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 ¦ÌM.	liposomes	34769299	Int J Mol Sci. 2021 Nov 1;22(21):11869. 	"Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. "	"25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses."
DRAMP29215	SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK	37	IBP20	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	48% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	"Mechanism of action:Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived."	[Ref.34057039]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=1.36 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=50.52 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=33.85 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=103.17 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=128.87 nM);##SARS-CoV-2 ¦¤H69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=111.41 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=79.09 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=88.49 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=92.16 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=73.86 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=228.4 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=817.21 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=471.54 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol(cholesterol)	None	L	No cytotoxicity information found in the reference(s) presented	Not found	34057039	Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.	"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y."	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
DRAMP29216	SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK	37	IBP21	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"Mechanism of action:Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived."	[Ref.34057039]Virus:SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=7.5 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=191.4 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=126.65 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	C16(palmitic acid)	None	L	No cytotoxicity information found in the reference(s) presented	Not found	34057039	Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.	"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y."	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
DRAMP29217	SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK	37	IBP22	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"Mechanism of action:Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived."	[Ref.34057039]Virus:SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=6.23 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=179.95 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=86.33 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	C18(stearic acid)	None	L	No cytotoxicity information found in the reference(s) presented	Not found	34057039	Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.	"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y."	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
DRAMP29218	SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK	37	IBP23	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"Mechanism of action:Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived."	[Ref.34057039]Virus:SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=39.07 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=1236.38 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=507.32 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Toc(tocophenol)	None	L	No cytotoxicity information found in the reference(s) presented	Not found	34057039	Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.	"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y."	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
DRAMP29219	SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK	37	IBP24	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	16% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	"Mechanism of action:Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived."	[Ref.34057039]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.33 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=3.77 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=2.89 nM);inhibition of live SARS-CoV-2 infection in Vero cells(IC50=8.97 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.29 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.5 nM);##SARS-CoV-2 ¦¤H69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.42 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.97 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.22 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.06 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=21.64 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=69.9 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=375.56 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=421.48 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG4-K(Chol)	None	L	[Ref.34057039]Huh-7 cells:CC50=6.6 ¦ÌM;Vero-E6 cells:CC50=13.67 ¦ÌM.	Not found	34057039	Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.	"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y."	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
DRAMP29220	SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK	37	IBP25	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	18% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	"Mechanism of action:Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived."	"[Ref.34057039]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.29 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=2.13 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=1.43 nM),inhibition of live SARS-CoV-2 infection in Vero cells(IC50=25.71 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.8 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.52 nM);##SARS-CoV-2 ¦¤H69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.56 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.71 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=5.87 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.76 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=17.69 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=48.5 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=353.22 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=336.14 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG5-K(Chol)	None	L	[Ref.34057039]Huh-7 cells:CC50=3.54 ¦ÌM;Vero-E6 cells:CC50=6.95 ¦ÌM.	Not found	34057039	Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.	"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y."	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
DRAMP29221	SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK	37	IBP26	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	"Mechanism of action:Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived."	[Ref.34057039]Virus:SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.26 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=3.05 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=1.82 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG6-K(Chol)	None	L	No cytotoxicity information found in the reference(s) presented	Not found	34057039	Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.	"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y."	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
DRAMP29222	SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK	37	IBP27	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	12% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	"Mechanism of action:Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived."	"[Ref.34057039]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.32 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=2.77 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=1.54 nM),inhibition of live SARS-CoV-2 infection in Vero cells(IC50=29.85 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.75 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.87 nM);##SARS-CoV-2 ¦¤H69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.56 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.55 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.18 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=8.25 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=24.95 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=60.08 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=179.53 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=231.18 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-K(Chol)	None	L	[Ref.34057039]Huh-7 cells:CC50=4.04 ¦ÌM;Vero-E6 cells:CC50=5.05 ¦ÌM.	Not found	34057039	Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.	"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y."	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
DRAMP29223	ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL	35	IBP02V1	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	0% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	The peptide is a fusion inhibitor against SARS-CoV-2.	[Ref.34344868]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=1.1¡À0.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=17.8 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=14.3 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.6¡À0.1 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=50 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=21.5 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=33.6¡À3.5 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=66.9¡À7.6 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=62.5¡À17.2 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=203.9¡À8.8 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-K(Chol)	None	L	[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10?¦ÌM.	liposomes	34344868	Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 	"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y."	SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.
DRAMP29224	DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL	36	IBP02V2	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	22% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	The peptide is a fusion inhibitor against SARS-CoV-2.	[Ref.34344868]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.6¡À0.03 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=20.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=18.1 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.4¡À0.04 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=19.3 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=20.8 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=56.5¡À9.4nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=55.3¡À2.8 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=67.5¡À8 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=535.7¡À44.6 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-K(Chol)	None	L	[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10?¦ÌM.	liposomes	34344868	Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 	"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y."	SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.
DRAMP29225	EISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL	36	IBP02V3	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	48% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	The peptide is a fusion inhibitor against SARS-CoV-2.	[Ref.34344868]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.4¡À0.02 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=14.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=17.5 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.2¡À0.02 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=40.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=14.4 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=48¡À5.8 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=38.5¡À6.2 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=75.8¡À9.9 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=545.7¡À0.9 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-K(Chol)	None	L	[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10?¦ÌM.	liposomes	34344868	Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 	"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y."	SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.
DRAMP29226	ELSGINASVVNLQKEIDRLNEVAKNLNESLIDLQEL	36	IBP02V4	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	59% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	The peptide is a fusion inhibitor against SARS-CoV-2.	[Ref.34344868]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.3¡À0.02 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=18.6 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=15.2 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.1¡À0.02 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=29.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=26.3 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=63¡À1.7 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=22.4¡À2.2 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=66.3¡À3.1 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=502¡À24.2 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-K(Chol)	None	L	[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10?¦ÌM.	liposomes	34344868	Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 	"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y."	SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.
DRAMP29227	SLTQINASVVNIQKEIDRLNEVAKNLNESLIDLQEL	36	IBP02V5	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	16% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	The peptide is a fusion inhibitor against SARS-CoV-2.	[Ref.34344868]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=2.1¡À0.5 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=21 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=23.5 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=1.3¡À0.1 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=98.8 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=27.5 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=65.9¡À13.2 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=68.4¡À9.7 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=70.8¡À8.7 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=1128.4¡À148.6 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-K(Chol)	None	L	[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10?¦ÌM.	liposomes	34344868	Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 	"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y."	SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.
DRAMP29228	SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL	36	MERS-LP	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	8% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	The peptide is a fusion inhibitor against SARS-CoV-2.	[Ref.34344868]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=102.9¡À7.2 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=5046¡À905.2 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=79.1¡À9.8 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=82.9¡À8.6 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-K(Chol)	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34344868	Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 	"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y."	SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.
DRAMP29229	SLDYINVTFLDLQDEMNRLQEAIKVLNQSYINLKDI	36	OC43-LP	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	22% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	The peptide is a fusion inhibitor against SARS-CoV-2.	[Ref.34344868]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=4.1¡À1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=82.8¡À22.1 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=2.4¡À0.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=97.5¡À5.9 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=250.4¡À39.7 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=5.2¡À0.5 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=416.5¡À227.5 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=2008.8¡À697.9 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-K(Chol)	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34344868	Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 	"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y."	SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.
DRAMP29230	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELK	37	EK1V1	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	39% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37 ¡ãC	Not found	None	The peptide is a fusion inhibitor against SARS-CoV-2.	[Ref.34344868]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=273.5¡À4.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=2672.1¡À384.5 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=214.5¡À20.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=1790.8¡À363.2 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=4370.3¡À719.7 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=499.8¡À163.3 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=487.2¡À41.3 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=1255.6¡À453.3 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Chol	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34344868	Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 	"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y."	SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.
DRAMP29231	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL	36	EK1V2	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	68% ¦Á-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 ¦ÌM and incubated at 37¡ãC	Not found	None	The peptide is a fusion inhibitor against SARS-CoV-2.	[Ref.34344868]Virus:##SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.9¡À0.2 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=87.2¡À8.3 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.5¡À0.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=106.5¡À5.4 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=252¡À5.6 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=1.1¡À0.3 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=59.4¡À13.1 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=503.3¡À20.9 nM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	PEG8-K(Chol)	None	L	No cytotoxicity information found in the reference(s) presented	liposomes	34344868	Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 	"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y."	SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.
DRAMP29232	ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL	35	P3	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Comment: No comments found on DRAMP database	[Ref.32482145]Virus:HCoV-19:inhibition of HCoV-19 S mediated cell¨Ccell fusion(EC50=0.72 ¦ÌM);neutralizing activities against pseudotype HCoV-19 virus(EC50=0.32 ¦ÌM);inhibition of authentic HCoV-19 virus infection in Vero E6 cells(EC50=0.58 ¦ÌM).	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Free	Free	None	L	No cytotoxicity information found in the reference(s) presented	Not found	32482145	Emerg Microbes Infect. 2020 Dec;9(1):1238-1241.	"Sun H, Li Y, Liu P, Qiao C, Wang X, Wu L, Liu K, Hu Y, Su C, Tan S, Zou S, Wu G, Yan J, Gao GF, Qi J, Wang Q. "	Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry.
DRAMP29233	XxXVXAaXXXX	11	"Alisporivir, Debio-025"	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Comment: No comments found on DRAMP database	"[Ref.32376613]Virus:SARS-CoV-2:Inhibition of infection in Vero E6 cells(EC50=0.46¡À0.04 ?M,E90=3.10¡À1.40 ¦ÌM).##[Ref.32568027]Virus:##SARS-CoV-2:Inhibition of infection in Vero E6 cells(EC50=4.9¡À1.3 ?M);##SARS-CoV:Inhibition of infection in Vero E6 cells(EC50=4.3¡À1.0 ?M)."	No hemolysis information or data found in the reference(s) presented in this entry	Cyclic	No specific N-terminal	No specific C-terminal	"The 'X' at position 1 is alpha-aminobutyric acid,position 2 is N-methylalanine,the 'V' at position 3 is N-methylalanine,the 'X' at position 5,8,9 are N-methylleucine,the 'X' at position 10 is N-methylvaline and position 11 is N-methyl-(4R)-4-[(E)-but-2-enyl]-4-methyl-L-threonyl"	"Mixed(D-Ala7,D-meth-Ala2)"	[Ref.32376613]Vero E6 cells:CC50>20?M.	Not found	32376613##32568027	Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00876-20. ##J Gen Virol. 2020 Sep;101(9):925-940.	"Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM, Ahmed-Belkacem A.##Ogando NS, Dalebout TJ, Zevenhoven-Dobbe JC, Limpens RWAL, van der Meer Y, Caly L, Druce J, de Vries JJC, Kikkert M, B¨¢rcena M, Sidorov I, Snijder EJ."	"Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).##SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology."
DRAMP29234	PxTXXLPX	8	"Plitidepsin, Aplidine"	No entry found	Not found	Not found	Synthetic construct	"Antimicrobial, Antiviral(SARS-CoV-2)"	Not found	Not found	Not found	None	Mechanism of action:The antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A (eukaryotic translation elongation factor 1A).	"[Ref.33495306]Virus:SARS-CoV-2:inhibition of replication In Vero E6 cells(IC50=0.70 nM,IC90=1.76 nM);inhibition of replication In hACE2-HEK293T cells(IC50=0.73 nM,IC90=0.88 nM);inhibition of replication In pneumocyte-like cells(IC50=1.62 nM,IC90=3.14 nM).##[Ref.35231500]Virus:##SARS-CoV-2 D614G:inhibition of replication in Vero E6 cells(IC50=5.2 nM);##SARS-CoV-2 Delta:inhibition of replication in Vero E6 cells(IC50=3.9 nM);##SARS-CoV-2 Omicron:inhibition of replication in Vero E6 cells(IC50=4.3 nM)."	No hemolysis information or data found in the reference(s) presented in this entry	Linear	Pyruvoyl	Free	"The 'X' at position 2 is N-methylleucine,position 4 is 4-amino-3-hydroxy-5-methyl-Heptanoic acid, position 5 is Hydroxyisovalerylpropionyl, and position 8 is N-methyl-4-methyl-tyrosine.There is a Sidechain-Mainchain Bond between position 3 and 8."	Mixed(D-meth-Leu2)	"[Ref.33495306]Vero E6 cells:CC10=0.36 nM,CC50=1.99 nM;hACE2-293T cells:CC10=2.00 nM,CC50>200 nM;pneumocyte-like cells:CC10=20.88 nM,CC50=65.43 nM."	Not found	35231500##33495306	Antiviral Res. 2022 Apr;200:105270.##Science. 2021 Feb 26;371(6532):926-931. 	"Sachse M, Tenorio R, Fern¨¢ndez de Castro I, Mu?oz-Basagoiti J, Perez-Zsolt D, Ra?ch-Regu¨¦ D, Rodon J, Losada A, Avil¨¦s P, Cuevas C, Paredes R, Segal¨¦s J, Clotet B, Vergara-Alert J, Izquierdo-Useros N, Risco C.##White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E, Jangra S, Uccellini MB, Rathnasinghe R, Coughlan L, Martinez-Romero C, Batra J, Rojc A, Bouhaddou M, Fabius JM, Obernier K, Dejosez M, Guill¨¦n MJ, Losada A, Avil¨¦s P, Schotsaert M, Zwaka T, Vignuzzi M, Shokat KM, Krogan NJ, Garc¨ªa-Sastre A. "	Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.##Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.